Hypersensitivity News and Research

RSS

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.

ACROBiosystems opens new Innovation laboratory in Delaware

January 18, 2018, ACROBiosystems officially opened its New Innovation laboratory in the Delaware Innovation Space in Wilmington, Delaware, USA, and held a grand opening ceremony.

From ACROBiosystems 7 Mar 2019

Abnormal timing found in the brains of people with autistic symptoms

The neural 'time windows' in certain small brain areas contribute to the complex cognitive symptoms of autism, new research suggests.

13 Feb 2019

Study may lead to a greater understanding of the mechanisms behind neuropathic pain

In animal models of a totally crushed peripheral nerve, the damaged axons are broken down, allowing healthy ones to regrow.

1 Feb 2019

Researchers compare treatment options for fecal incontinence

It is a common health problem that causes uncommon personal discomfort. Fecal incontinence, or accidental stool leakage, affects some 8 to 10 percent of the 325 million people in the United States. In up to half of patients, there is both fecal and urinary incontinence.

29 Jan 2019

Mouse studies challenge 'inhibition' theory of autism

A detailed study of four mouse models of autism challenges the most common assumption about what goes wrong in brain circuits to cause disease symptoms.

21 Jan 2019

Noninvasive hearing test may assist with early detection of autism spectrum disorders

A noninvasive hearing test may assist with early detection and diagnosis of autism spectrum disorders, according to research published in the Journal of the American Osteopathic Association.

7 Jan 2019

Common food additive could cause celiac disease, review says

Research suggests that celiac disease could be caused by a bacterial enzyme used to manufacture sausages, cheese, bread and other processed foods.

7 Jan 2019

Novel insight on inflammatory regulation could pave way for effective pain therapies

A novel way in which the inflammatory response to pain is regulated has been described in the open-access journal eLife.

19 Dec 2018

Study describes mechanism that makes people more vulnerable to hunger-causing stimuli

The holiday season is a hard one for anyone watching their weight. The sights and smells of food are hard to resist.

13 Dec 2018

FDA approves new drug for treatment of rare autoimmune disorder

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

29 Nov 2018

FDA approves antibacterial drug to treat travelers' diarrhea

The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

17 Nov 2018

Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.

16 Nov 2018

Monash researchers provide insight into intricate peptide changes affecting immune system

Human leukocyte antigen molecules are a group of proteins that help the immune system identify foreign invaders such as viruses and bacteria and which impact a wide variety of clinical outcomes including infection and cancer.

8 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

29 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Hypersensitivity News and Research

ACROBiosystems opens new Innovation laboratory in Delaware

Abnormal timing found in the brains of people with autistic symptoms

Study may lead to a greater understanding of the mechanisms behind neuropathic pain

Researchers compare treatment options for fecal incontinence

Mouse studies challenge 'inhibition' theory of autism

Noninvasive hearing test may assist with early detection of autism spectrum disorders

Common food additive could cause celiac disease, review says

Novel insight on inflammatory regulation could pave way for effective pain therapies

Study describes mechanism that makes people more vulnerable to hunger-causing stimuli

FDA approves new drug for treatment of rare autoimmune disorder

FDA approves antibacterial drug to treat travelers' diarrhea

Nexus announces availability of Arsenic Trioxide Injection in the US

Monash researchers provide insight into intricate peptide changes affecting immune system

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News